rituximab,ibrutinib
janssen,abbvie
['rituximab', 'mantle,(-dismantle)', 'lymsm', 'cml', 'ritux', 'ibru']
first at #17icml mantle cell session: icml-2015 study of mrd-adapted rituximab + ibrutinib in indolent mcl. - 50 pts (15% tp53mut)
- orr 84% (cr 82%, mrd- 80%)
- mdor 67 mo, mpfs &gt;6 years
- 26% discontinuation d/t aes
doesn't change w&amp;w; tp53 still with poor prognosis #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈